| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.04B | 2.71B | 2.51B | 3.90B | 9.90B | 5.77B |
| Gross Profit | 127.66M | 555.56M | -50.28M | 113.52M | 1.25B | 980.32M |
| EBITDA | -59.80M | 295.14M | -145.86M | -325.93M | 581.55M | 1.09B |
| Net Income | -1.41B | -1.24B | -563.97M | -912.78M | 228.33M | 98.74M |
Balance Sheet | ||||||
| Total Assets | 56.83B | 57.20B | 56.35B | 57.39B | 61.07B | 67.52B |
| Cash, Cash Equivalents and Short-Term Investments | 171.08M | 158.10M | 152.22M | 189.51M | 556.87M | 1.65B |
| Total Debt | 22.59B | 22.79B | 22.18B | 21.25B | 20.95B | 23.52B |
| Total Liabilities | 44.63B | 44.83B | 42.57B | 43.01B | 45.64B | 52.41B |
| Stockholders Equity | 9.70B | 9.93B | 11.17B | 11.73B | 12.71B | 12.49B |
Cash Flow | ||||||
| Free Cash Flow | 632.07M | 678.26M | 452.11M | 413.47M | 4.07B | 4.67B |
| Operating Cash Flow | 630.31M | 679.53M | 512.92M | 606.31M | 4.35B | 4.94B |
| Investing Cash Flow | 105.81M | 146.72M | 58.95M | -305.41M | 184.15M | -2.78B |
| Financing Cash Flow | -770.21M | -830.50M | -627.40M | -630.90M | -5.65B | -1.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
48 Neutral | HK$221.84M | -5.21 | -5.13% | ― | -76.39% | -1142.86% | |
44 Neutral | HK$311.26M | -0.18 | -34.31% | ― | -63.41% | 77.97% | |
41 Neutral | HK$617.77M | -0.41 | -13.99% | ― | -0.38% | -296.42% | |
41 Neutral | HK$129.20M | -0.04 | -35.96% | ― | -5.63% | -36.30% | |
40 Underperform | HK$126.66M | -0.01 | ― | ― | -70.13% | -16.86% |
Glory Health Industry Limited has provided a quarterly update on efforts to address the disclaimer of opinion issued by its auditors on the 2024 consolidated financial statements, which stemmed from doubts over the group’s ability to realize assets and meet liabilities in the normal course of business. Since its last update, the group has secured an extension approval from Bank of Tianjin on a RMB1.314 billion loan, but broader debt restructuring talks with financial institutions and other creditors remain ongoing. Several key asset disposal and project transfer initiatives, including the overall transfers of its Shenyang company and Foshan Shengpingli project, the sale of Beijing North Fifth Building, and the disposal of Hainan Yunlong Property, are still in the stage of seeking buyers and negotiating terms, with management indicating that successful completion would ease liquidity pressures and significantly reduce total debt. The group is also continuing applications to relevant government authorities for the return of land tied to its Shenyang and Chongming Island projects, and has pledged to make further announcements as material progress is achieved, underscoring the critical importance of these measures for its financial stability and creditor confidence.
The most recent analyst rating on (HK:2329) stock is a Hold with a HK$0.12 price target. To see the full list of analyst forecasts on Guorui Properties Ltd stock, see the HK:2329 Stock Forecast page.
Glory Health Industry Limited, a company incorporated in the Cayman Islands, has announced a significant update regarding its board composition and compliance with stock exchange listing rules. Following the resignation of Mr. Yuan Hao as an independent non-executive director, the company faced challenges in appointing a suitable replacement due to concerns about the property sector’s operating conditions in China and misalignment with candidates’ appointment terms. Consequently, the company applied for and was granted a waiver from strict compliance with certain listing rules, allowing more time to appoint Mr. Wang Shiyu as an independent non-executive director. This waiver, subject to change by the stock exchange, highlights the company’s proactive measures to maintain compliance and stabilize its board amid challenging market conditions.
The most recent analyst rating on (HK:2329) stock is a Hold with a HK$0.12 price target. To see the full list of analyst forecasts on Guorui Properties Ltd stock, see the HK:2329 Stock Forecast page.
Glory Health Industry Limited has appointed Mr. Wang Shiyu as an independent non-executive director, chairman of the internal control committee, and a member of the audit committee, effective December 1, 2025. Mr. Wang brings extensive experience in investment banking, mergers and acquisitions, and corporate globalization, which is expected to strengthen the company’s governance and strategic direction.
The most recent analyst rating on (HK:2329) stock is a Hold with a HK$0.11 price target. To see the full list of analyst forecasts on Guorui Properties Ltd stock, see the HK:2329 Stock Forecast page.
Glory Health Industry Limited has announced the composition of its board of directors and the establishment of four committees to oversee various aspects of its operations. The board comprises both executive and independent non-executive directors, with Zhang Zhangsun serving as the chairman. This announcement highlights the company’s commitment to structured governance and operational oversight, which may enhance its industry positioning and stakeholder confidence.
The most recent analyst rating on (HK:2329) stock is a Hold with a HK$0.11 price target. To see the full list of analyst forecasts on Guorui Properties Ltd stock, see the HK:2329 Stock Forecast page.